# US 2013/0281372 A1 · Methods to enhance rnai oligonucleotide delivery to respiratory epithelial cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281372 A1
- Document ID: US20130281372A1
- Status: Published application
- Kind: A1
- Application number: 13/828,488
- Filed: 2013-03-14
- Published: 2013-10-24
- Earliest claimed: 2012-04-20
- Assignees: University of Iowa Research Foundation
- Applicants: University of Iowa Research Foundation
- Inventors: Paul B. McCray, JR.; Beverly L. Davidson; Sateesh Krishnamurthy
- Web page: https://patentgrep.com/patent/US20130281372A1

## CPC

- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a sensitizing agent followed by contacting the cell with a therapeutic RNAi agent.

## Claims

### Claim 1

A method of reducing a level of a target mRNA in a well-differentiated airway epithelial cell comprising contacting the cell with a sensitizing agent followed by contacting the cell with a therapeutic RNAi agent, wherein the mRNA level of the target mRNA is reduced by at least 1% as compared to a control cell that has not been contacted with the sensitizing compound.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mRNA level of the target mRNA is reduced by at least 10%.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mRNA level of the target mRNA is reduced by at least 20%.

### Claim 4 (depends on 1)

The method of claim 1, wherein well differentiated cells are more than five days old.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sensitizing agent is a small molecule PI3K inhibitor, EGF, LY-294002, wortmannin or triciribine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the RNAi molecule is an siRNA, an miRNA, and/or an anti-sense oligonucleotide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell is contacted on its mucosal surface.

### Claim 8 (depends on 1)

The method of claim 1, wherein the airway epithelial cell is a lung cell, a nasal cell, a tracheal cell, a bronchial cell, a bronchiolar or alveolar epithelial cell.

### Claim 9

A method of treating a subject having an airway epithelial disease comprising administering to the subject an effective amount of a sensitizing agent and an effective amount of a therapeutic agent to alleviate the symptoms of the airway epithelial disease by inducing a therapeutic effect.

### Claim 10 (depends on 9)

The method of claim 9, wherein the sensitizing agent is administered orally.

### Claim 11 (depends on 9)

The method of claim 9, wherein the sensitizing agent is administered by inhalation.

### Claim 12 (depends on 9)

The method of claim 9, wherein the sensitizing agent is administered by aerosol, dry powder, bronchoscopic instillation, or intra-airway (tracheal or bronchial) aerosol.

### Claim 13 (depends on 9)

The method of claim 9, wherein the therapeutic agent is administered orally, by inhalation, by aerosol, dry powder, bronchoscopic instillation, or intra-airway (tracheal or bronchial) aerosol.

### Claim 14 (depends on 9)

The method of claim 9, wherein the airway epithelial disease is cystic fibrosis.

### Claim 15 (depends on 9)

The method of claim 9, wherein the subject is a mammal.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is a human.

### Claim 17 (depends on 9)

The method of claim 9, wherein the therapeutic RNAi agent is present within a pharmaceutical composition.

### Claim 18 (depends on 9)

The method of claim 9, wherein the symptoms are reduced by at least 1%.

### Claim 19 (depends on 9)

The method of claim 9, wherein the sensitizing agent is EGF, a small molecule PI3K inhibitor, LY-294002, wortmannin or triciribine.

### Claim 20

A kit for reducing a level of a target mRNA in a well-differentiated PAE cell comprising
(a) a sensitizing agent,
(b) a therapeutic RNAi molecule, and
(c) instructions for contacting the cell with the sensitizing compound and the RNAi molecule to reduce the mRNA level of the target mRNA by at least 1% as compared to a control cell that has not been contacted with the sensitizing compound.
